221 related articles for article (PubMed ID: 24807804)
1. Periocular Scleromyxedema.
Qureshi F; Dharmasena A; Leatherbarrow B
Ophthalmic Plast Reconstr Surg; 2015; 31(5):e119-20. PubMed ID: 24807804
[TBL] [Abstract][Full Text] [Related]
2. Managing scleromyxedema with intravenous immunoglobulin: acute worsening of scleromyxedema with biclonal gammopathy.
Manousaridis I; Loeser C; Goerdt S; Hassel JC
Acta Dermatovenerol Alp Pannonica Adriat; 2010 Dec; 19(4):15-9. PubMed ID: 21390475
[TBL] [Abstract][Full Text] [Related]
3. An unusual presentation of scleromyxedema as inflammatory myopathy.
Vysakha KV; Poyuran R; Nair SS; Nair M
Acta Myol; 2019 Mar; 38(1):13-16. PubMed ID: 31309176
[TBL] [Abstract][Full Text] [Related]
4. Treatment of scleromyxedema and the dermatoneuro syndrome with intravenous immunoglobulin.
Rey JB; Luria RB
J Am Acad Dermatol; 2009 Jun; 60(6):1037-41. PubMed ID: 19249127
[TBL] [Abstract][Full Text] [Related]
5. Scleromyxedema with subcutaneous nodules: successful treatment with thalidomide and intravenous immunoglobulin.
Dolenc-Voljč M; Jurčić V; Hočevar A; Tomšič M
Case Rep Dermatol; 2013; 5(3):309-15. PubMed ID: 24348379
[TBL] [Abstract][Full Text] [Related]
6. Scleromyxedema: a multicenter study of characteristics, comorbidities, course, and therapy in 30 patients.
Rongioletti F; Merlo G; Cinotti E; Fausti V; Cozzani E; Cribier B; Metze D; Calonje E; Kanitakis J; Kempf W; Stefanato CM; Marinho E; Parodi A
J Am Acad Dermatol; 2013 Jul; 69(1):66-72. PubMed ID: 23453242
[TBL] [Abstract][Full Text] [Related]
7. [Monoclonal immunoglobulin (M-Ig) and skin diseases from the group of mucinoses--scleredema adultorum Buschke and scleromyxedema. Description of four cases and an overview of therapies].
Adam Z; Szturz P; Krejčí M; Vašků V; Pour L; Michalková E; Ševčíková S; Čermáková Z; Veselý K; Vaníček J; Pourová E; Král Z; Mayer J
Vnitr Lek; 2015 Dec; 61(12):1072-87. PubMed ID: 26806503
[TBL] [Abstract][Full Text] [Related]
8. [Atypical scleromyxedema with a granulomatous histological pattern and delayed sclerosis].
de Cambourg G; Goussot R; Wettlé C; Cribier B
Ann Dermatol Venereol; 2016 May; 143(5):382-6. PubMed ID: 26969478
[TBL] [Abstract][Full Text] [Related]
9. Scleromyxedema: clinical diagnosis and autopsy findings.
Sala AC; Cunha PR; Pinto CA; Alves CA; Paiva IB; Araujo AP
An Bras Dermatol; 2016; 91(5 suppl 1):48-50. PubMed ID: 28300892
[TBL] [Abstract][Full Text] [Related]
10. Scleromyxedema in a 21 year old female patient with acute lymphoblastic leukemia: a case report.
Rabee H; Tayem L; Gharbeyah M; Abugaber D
BMC Dermatol; 2020 Dec; 20(1):18. PubMed ID: 33276772
[TBL] [Abstract][Full Text] [Related]
11. Scleromyxedema without paraproteinemia.
Abarzúa AA; Giesen LF; Sandoval MO; González SB
Int J Dermatol; 2014 Aug; 53(8):971-4. PubMed ID: 24527753
[TBL] [Abstract][Full Text] [Related]
12. Lichen myxedematosus associated with monoclonal gammopathy of undetermined significance: A case report and a review of Japanese patients.
Shibao K; Watanabe R; Saito A; Ishii Y; Nakamura Y; Ishitsuka Y; Okiyama N; Fujisawa Y; Fujimoto M
J Dermatol; 2019 Jan; 46(1):e32-e33. PubMed ID: 29963716
[No Abstract] [Full Text] [Related]
13. Lichen myxedematosus (papular mucinosis): new concepts and perspectives for an old disease.
Rongioletti F
Semin Cutan Med Surg; 2006 Jun; 25(2):100-4. PubMed ID: 16908401
[TBL] [Abstract][Full Text] [Related]
14. Intravenous gammaglobulin and thalidomide may be an effective therapeutic combination in refractory scleromyxedema: case report and discussion of the literature.
Efthimiou P; Blanco M
Semin Arthritis Rheum; 2008 Dec; 38(3):188-94. PubMed ID: 18221985
[TBL] [Abstract][Full Text] [Related]
15. Scleromyxedema with multiple systemic involvement: Successful treatment with intravenous immunoglobulin.
Kim S; Park TH; Lee SM; Kim YH; Cho MK; Whang KU; Kim HS
Dermatol Ther; 2020 May; 33(3):e13378. PubMed ID: 32250023
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy of intravenous immunoglobulin in Arndt-Gottron scleromyxedema].
Lopez L; Wierzbicka-Hainaut E; Villers A; Guillet G
Ann Dermatol Venereol; 2009 Apr; 136(4):330-6. PubMed ID: 19361699
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Efficacy of Treatment with Intravenous Immunoglobulin in Scleromyxedema.
Baglama Š; Trčko K
Acta Dermatovenerol Croat; 2020 Jul; 28(1):24-28. PubMed ID: 32650847
[TBL] [Abstract][Full Text] [Related]
18. Case report: Scleromyxedema associated with a monoclonal gammapathy: Successful treatment with intravenous immunoglobulins.
Wang SS; Chen QY; Xiang LH
Front Immunol; 2022; 13():1099918. PubMed ID: 36713453
[TBL] [Abstract][Full Text] [Related]
19. Scleromyxedema Without Monoclonal Gammopathy Treated with Intravenous Immunoglobulins.
Letzelter M; Grimaux X
Acta Dermatovenerol Croat; 2021 Apr; 291(1):51-53. PubMed ID: 34477065
[TBL] [Abstract][Full Text] [Related]
20. Case for diagnosis. Lichen myxedematosus.
Rebellato PR; Carbonar MB; Tabuti NI; Rastelli GJ
An Bras Dermatol; 2016; 91(6):842-843. PubMed ID: 28099617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
